Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Food and Drug Administration chief Scott Gottlieb is making a pitch to change the reimbursement model for antimicrobial drugs that target multidrug-resistant infections.
Purdue Pharmaceuticals is facing a new legal challenge over its OxyContin marketing practices.
The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.
Elizabeth Holmes and beleaguered Theranos finally caught a break. Last week U.S. Magistrate Judge Nathanael Cousins shot down the hopes of some investors in filing a class action lawsuit against the company.
The ink is barely dry on the recently-passed “Right to Try Act,” and the law’s author, Sen. Ron Johnson (R-Wis.) and U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb are butting heads.
FDA Commissioner Scott Gottlieb released a statement on new policies aimed to combat the practice of using certain agency requirements to block timely generic drug entry.
President Donald Trump signed the recently-passed ‘Right to Try Act,’ which will give terminally ill patients the right to seek access to medications that have yet to be approved in order to save their lives.
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
With the ever-increasing concerns of the opioid crisis facing the United States, the U.S. Food and Drug Administration has launched an “innovation challenge” to spur on the development of medical devices that can combat the crisis and help prevent and treat opioid use disorder.
Purdue Pharmaceuticals has named a new head of corporate social responsibility as it continues to grapple with negative attention due to the rampant opioid crisis across the United States.